Litigation Details for TEVA PHARMACEUTICALS USA, INC. v. AZAR, II (D.D.C. 2018)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2018-10-17
Court	District Court, District of Columbia	Date Terminated	2019-02-25
Cause	05:702 Administrative Procedure Act	Assigned To	Randolph Daniel Moss
Jury Demand	None	Referred To
Patents	8,629,111
Link to Docket	External link to docket

The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-17	1		announced that it would issue U.S. Patent No. 8,629,111 (“the ‘111 patent”) on January 14, 2014. Official…initially listed two patents in the Orange Book: U.S. Patent Nos. 4,839,342 (“the ‘342 patent”), which expired…intertwined patent-submission, patent- listing, Paragraph IV certification, Paragraph IV notice, patent-litigation… innovators’ patent rights. Whenever a brand manufacturer believes it holds valid patent rights on an…company to file with FDA “the patent number and the expiration date of any patent which claims the drug …	External link to document
2019-02-25	47		related patents to the Orange Book, beginning with U.S. Patent No. 8,629,111 (“the ‘111 patent”), which…include “the patent number and the expiration date of any patent . . . to which a claim of patent infringement…“the ‘342 patent”) and No. 5,474,979 (“the ‘979 patent”). Id. The ‘342 patent expired on August 2, 2009…unexpired patent listed in the Orange Book” for Restasis® was the ‘979 patent. Id. That patent was due …FDA of the patent number and expiration date. Id. § 355(c)(2). The FDA then lists this patent information	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document